Abstract
The preferential loss of dopaminergic neurons in the substantia nigra pars compacta is one of the pathological hallmarks characterizing Parkinson’s disease. Although the pathogenesis of this disorder is not fully understood, oxidative stress plays a central role in the onset and/or progression of Parkinson’s disease and dopamine itself has been suggested to participate in the preferential neuronal degeneration through the induction of oxidative conditions. In fact, the accumulation of dopamine into the cytosol can lead to the formation of reactive oxygen species as well as highly reactive dopamine-quinones. In the present work, we first analyzed the cellular damage induced by the addition of dopamine (DA) in the culture medium of SH-SY5Y cells, discriminating whether the harmful effects were related to the generation of reactive oxygen species or to the toxicity associated to dopamine-derived quinones. Then, we tested and demonstrated the capability of the antioxidant enzymes SOD1 and SOD2 to protect cells from the noxious effects induced by DA treatment. Our results support further exploration of superoxide dismutating molecules as a therapeutic strategy against Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Banerjee K, Munshi S, Sen O, Pramanik V, Roy Mukherjee T, Chakrabarti S (2014) Dopamine cytotoxicity involves both oxidative and nonoxidative pathways in SH-SY5Y cells: potential role of alpha-synuclein overexpression and proteasomal inhibition in the etiopathogenesis of Parkinson’s disease. Parkinsons Dis 2014:878935. https://doi.org/10.1155/2014/878935
Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38:515–517. https://doi.org/10.1038/ng1769
Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson’s disease. J Neurochem 73:1127–1137
Biosa A, Arduini I, Soriano ME, Giorgio V, Bernardi P, Bisaglia M, Bubacco L (2018a) Dopamine oxidation products as mitochondrial endotoxins, a potential molecular mechanism for preferential neurodegeneration in Parkinson’s disease. ACS Chem Neurosci 9:2849–2858. https://doi.org/10.1021/acschemneuro.8b00276
Biosa A, Sanchez-Martinez A, Filograna R, Terriente-Felix A, Alam SM, Beltramini M, Bubacco L, Bisaglia M, Whitworth AJ (2018b) Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss. Hum Mol Genet 27:1618–1629. https://doi.org/10.1093/hmg/ddy069
Bisaglia M, Greggio E, Maric D, Miller DW, Cookson MR, Bubacco L (2010a)Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci 11:41. https://doi.org/10.1186/1471-2202-11-41
Bisaglia M, Soriano ME, Arduini I, Mammi S, Bubacco L (2010b) Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochim Biophys Acta 1802:699–706. https://doi.org/10.1016/j.bbadis.2010.06.006
Bisaglia M, Greggio E, Beltramini M, Bubacco L (2013) Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson’s disease therapies. FASEB J 27:2101–2110. https://doi.org/10.1096/fj.12-226852
Bisaglia M, Filograna R, Beltramini M, Bubacco L (2014) Are dopamine derivatives implicated in the pathogenesis of Parkinson’s disease? Ageing Res Rev 13:107–114. https://doi.org/10.1016/j.arr.2013.12.009
Bonora M, Pinton P (2014) The mitochondrial permeability transition pore and cancer: molecular mechanisms involved in cell death. Front Oncol 4:302. https://doi.org/10.3389/fonc.2014.00302
Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, Savas JN, Kiskinis E, Zhuang X, Krüger R, Surmeier DJ, Krainc D (2017) Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science 357:1255–1261. https://doi.org/10.1126/science.aam9080
Cannon JR, Greenamyre JT (2013)Gene-environment interactions in Parkinson’s disease: specific evidence in humans and mammalian models. Neurobiol Dis 57:38–46. https://doi.org/10.1016/j.nbd.2012.06.025
De Lazzari F, Bubacco L, Whitworth AJ, Bisaglia M (2018) Superoxide radical dismutation as new therapeutic strategy in Parkinson’s disease. Aging Dis 9:716–728. https://doi.org/10.14336/AD.2017.1018
Emdadul Haque M, Asanuma M, Higashi Y, Miyazaki I, Tanaka K, Ogawa N (2003)Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 1619:39–52
Ermak G, Davies KJ (2002) Calcium and oxidative stress: from cell signaling to cell death. Mol Immunol 38:713–721
Filograna R, Civiero L, Ferrari V, Codolo G, Greggio E, Bubacco L, Beltramini M, Bisaglia M (2015) Analysis of the catecholaminergic phenotype in human SH-SY5Y and BE(2)-M17 neuroblastoma cell lines upon differentiation. PLoS One 10:e0136769. https://doi.org/10.1371/journal.pone.0136769
Filograna R, Beltramini M, Bubacco L, Bisaglia M (2016a)Anti-oxidants in Parkinson’s disease therapy: a critical point of. View Curr Neuropharmacol 14:260–271. https://doi.org/10.2174/1570159X1403160303151355
Filograna R, Godena VK, Sanchez-Martinez A, Ferrari E, Casella L, Beltramini M, Bubacco L, Whitworth AJ, Bisaglia M (2016b) Superoxide dismutase (SOD)-mimetic M40403 is protective in cell and fly models of paraquat toxicity: implications for Parkinson disease. J Biol Chem 291:9257–9267. https://doi.org/10.1074/jbc.M115.708057
Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55:259–272
Ganguly U, Ganguly A, Sen O, Ganguly G, Cappai R, Sahoo A, Chakrabarti S (2019) Dopamine cytotoxicity on SH-SY5Y cells: involvement of alpha-synuclein and relevance in the neurodegeneration of sporadic Parkinson’s disease. Neurotox Res 35:898–907. https://doi.org/10.1007/s12640-019-0001-0
Gimenez-Xavier P et al (2006) The decrease of NAD(P) H has a prominent role in dopamine toxicity. Biochim Biophys Acta 1762:564–574. https://doi.org/10.1016/j.bbadis.2006.02.003
Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633–643
Greggio E, Bergantino E, Carter D, Ahmad R, Costin GE, Hearing VJ, Clarimon J, Singleton A, Eerola J, Hellstrom O, Tienari PJ, Miller DW, Beilina A, Bubacco L, Cookson MR (2005) Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson’s disease. J Neurochem 93:246–256. https://doi.org/10.1111/j.1471-4159.2005.03019.x
Hayashi T, Rizzuto R, Hajnoczky G, Su TP (2009) MAM: more than just a housekeeper. Trends Cell Biol 19:81–88. https://doi.org/10.1016/j.tcb.2008.12.002
Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4:600–609. https://doi.org/10.1038/ncpneuro0924
Izumi Y, Sawada H, Yamamoto N, Kume T, Katsuki H, Shimohama S, Akaike A (2005) Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells. J Neurosci Res 82:126–137. https://doi.org/10.1002/jnr.20595
Jana S, Sinha M, Chanda D, Roy T, Banerjee K, Munshi S, Patro BS, Chakrabarti S (2011) Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson’s disease. Biochim Biophys Acta 1812:663–673. https://doi.org/10.1016/j.bbadis.2011.02.013
Klegeris A, Korkina LG, Greenfield SA (1995) Autoxidation of dopamine: a comparison of luminescent and spectrophotometric detection in basic solutions. Free Radic Biol Med 18:215–222
Lai CT, Yu PH (1997)Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol 53:363–372
Malhotra JD, Kaufman RJ (2007) Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal 9:2277–2293. https://doi.org/10.1089/ars.2007.1782
Puspita L, Chung SY, Shim JW (2017) Oxidative stress and cellular pathologies in Parkinson’s disease. Mol Brain 10:53. https://doi.org/10.1186/s13041-017-0340-9
Solomon EI, Sundaram UM, Machonkin TE (1996) Multicopper oxidases and oxygenases. Chem Rev 96:2563–2606. https://doi.org/10.1021/cr950046o
Surmeier DJ (2018) Determinants of dopaminergic neuron loss in Parkinson’s disease. FEBS J 285:3657–3668. https://doi.org/10.1111/febs.14607
Willems PH, Rossignol R, Dieteren CE, Murphy MP, Koopman WJ (2015) Redox homeostasis and mitochondrial dynamics. Cell Metab 22:207–218. https://doi.org/10.1016/j.cmet.2015.06.006
Zelko IN, Mariani TJ, Folz RJ (2002) Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD(SOD3) gene structures, evolution, and expression. Free Radic Biol Med 33:337–349
Zeng XS, Geng WS, Jia JJ, Chen L, Zhang PP (2018) Cellular and molecular basis of neurodegeneration in Parkinson disease. Front Aging Neurosci 10:109. https://doi.org/10.3389/fnagi.2018.00109
Zorov DB, Juhaszova M, Sollott SJ (2014) Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94:909–950. https://doi.org/10.1152/physrev.00026.2013
Zucca FA, Basso E, Cupaioli FA, Ferrari E, Sulzer D, Casella L, Zecca L (2014) Neuromelanin of the human substantia nigra: an update. Neurotox Res 25:13–23. https://doi.org/10.1007/s12640-013-9435-y
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Biosa, A., De Lazzari, F., Masato, A. et al. Superoxide Dismutases SOD1 and SOD2 Rescue the Toxic Effect of Dopamine-Derived Products in Human SH-SY5Y Neuroblastoma Cells. Neurotox Res 36, 746–755 (2019). https://doi.org/10.1007/s12640-019-00078-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-019-00078-y